BASF Agricultural Solutions UK

Winter barley disease control

Dr Jon Helliwell, Business Development Manager

If managed correctly, barley can produce very good returns through both increased yield and quality. Barley yield is determined by ear number (sink limited), unlike wheat which is primarily source limited in the UK. Therefore, a focus on early tiller retention remains key in our barley crops. Understanding exactly what different barley actives are now providing is key to generating both the strongest levels of disease control, and the construction of a sustainable program.

T1 focus in 2021

Rhynchosporium, net blotch and mildew control remains important to early tiller retention.


  • Xemium® is the most effective active ingredient on Rhynchosporium.
  • Both F500® and Revysol® exhibit a strong level of efficacy.
  • Adding prothioconazole to the strongest barley actives available in Xemium® and F500® gives a robust start to early season rhynchosporium control.


  • With the loss of fenpropimorph, prothioconazole and Revysol® remain key actives for mildew suppression in barley.

Net blotch

  • There is now reduced SDHI sensitivity to net blotch within the UK population, due to the G79R mutation.
  • Strobilurin performance is variable across actives (due to partial resistance in the F129L mutation), but F500® still remains strong and has a vital part in the program.
  • Inclusion of F500® gives strong support to prothioconazole, as its own performance continues to erode.

T2 focus in 2021

The T2 spray should target ramularia, with continued activity on primary disease control and consideration for straw quality also important. With the loss of chlorothalonil, late season disease control in barley now requires a different mindset. Ramularia exhibits reduced sensitivity to SDHIs, strobilurins and most azoles, and there is clear evidence that symptoms are worse if the crop is stressed by early disease, large tank mixes or weather. Therefore, a combination of appropriate product selection, improving the reliability of primary disease control, and reducing early season stresses will impact positively on the ramularia risk.

  • In the past, adequate disease control of the key diseases was acceptable.
  • Going forwards, a comprehensive approach to disease control at T1 & T2 sets the foundation for improving the reliability of achieving acceptable ramularia control.
  • The inclusion of Xemium® and F500® early in the program remain key early stress mitigators within barley, particularly under drought conditions.
  • The combination of Revysol® and Xemium® within Revystar® XE retains its market-leading position against ramularia in independent trials, and should be considered a core application at T2.

  • Watch the AHDB Fungicide performance conference 2020 on barley here.
  • The 2020 AHDB Fungicide performance guide can be uploaded here.

Xemium® effects on straw breakdown

Summer rainfall often results in rapid growth in barley crops. This growth is usually relatively weak, and crops are therefore more susceptible to brackling. As well as effectively controlling disease, fungicides containing Xemium® have been proven to reduce brackling and necking in barley. Any delayed harvest further exacerbates this head loss in barley, so strengthening the straw to mitigate this becomes important. Revystar® XE has been demonstrated to reduce brackling and can successfully compliment an effective PGR program in barley.

University College Dublin – Fermoy (County Cork, Ireland) – 2019

T2 application only – 82% brackling in untreated.

Barley Disease Control Webinar

In a recent webinar, we discussed barley disease control, with guest speakers Professor Fiona Burnett from SRUC, and David Leahy from BASF. The expert panel reviewed the main barley diseases and explored fungicide performances, straw quality, and stress management.

Watch the full webinar on catch up


F500®, Comet® 200, Revystar® XE, Revysol® and Xemium® are registered trademarks of BASF. Revystar® XE contains Revysol® and Xemium®. Revysol® contains mefentrifluconazole. Xemium® contains fluxapyroxad. Comet® 200 contains pyraclostrobin. Always read the label and product information before use. For further product information including warning phrases and symbols, you can refer to

© BASF 2021 | All rights reserved. All other brand names used on this publication are Trademarks of other manufacturers in which proprietary rights may exist.